CY1123933T1 - Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης - Google Patents

Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης

Info

Publication number
CY1123933T1
CY1123933T1 CY20211100046T CY211100046T CY1123933T1 CY 1123933 T1 CY1123933 T1 CY 1123933T1 CY 20211100046 T CY20211100046 T CY 20211100046T CY 211100046 T CY211100046 T CY 211100046T CY 1123933 T1 CY1123933 T1 CY 1123933T1
Authority
CY
Cyprus
Prior art keywords
lorazepam
sustained release
extended release
release formulations
pellets
Prior art date
Application number
CY20211100046T
Other languages
English (en)
Inventor
Douglas A. Saltel
Michael Vachon
Original Assignee
Edgemont Pharmaceuticals, Llc Liquidating Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50064764&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123933(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals, Llc Liquidating Trust filed Critical Edgemont Pharmaceuticals, Llc Liquidating Trust
Publication of CY1123933T1 publication Critical patent/CY1123933T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Μία φαρμακευτική σύνθεση για χορήγηση λοραζεπάμης κατά παρατεταμένο τρόπο υλοποιείται με φαρμακευτικά σφαιρίδια παρατεταμένης αποδέσμευσης λοραζεπάμης. Η σύνθεση τυπικά περιέχει σφαιρίδια παρατεταμένης αποδέσμευσης λοραζεπάμης και σφαιρίδια καθυστερούμενης παρατεταμένης αποδέσμευσης λοραζεπάμης. Η σύνθεση μπορεί να παράσχει χορήγηση άπαξ ημερησίως η οποία διατηρεί θεραπευτική δράση διάρκειας 24 ωρών υπό συνθήκες σταθερής κατάστασης.
CY20211100046T 2013-01-09 2021-01-21 Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης CY1123933T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750797P 2013-01-09 2013-01-09
US201361762833P 2013-02-08 2013-02-08
PCT/US2014/010854 WO2014110245A1 (en) 2013-01-09 2014-01-09 Sustained release formulations of lorazepam

Publications (1)

Publication Number Publication Date
CY1123933T1 true CY1123933T1 (el) 2022-05-27

Family

ID=50064764

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100046T CY1123933T1 (el) 2013-01-09 2021-01-21 Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης

Country Status (30)

Country Link
US (3) US8999393B1 (el)
EP (1) EP2943185B1 (el)
JP (2) JP6039823B2 (el)
KR (1) KR102318274B1 (el)
CN (1) CN105209018B (el)
AU (1) AU2014205440B2 (el)
BR (1) BR112015016304A8 (el)
CA (1) CA2897302C (el)
CL (1) CL2015001920A1 (el)
CY (1) CY1123933T1 (el)
DK (1) DK2943185T3 (el)
ES (1) ES2856181T3 (el)
HK (1) HK1213770A1 (el)
HR (1) HRP20210236T1 (el)
HU (1) HUE054005T2 (el)
IL (1) IL239777B (el)
LT (1) LT2943185T (el)
MX (1) MX367364B (el)
NZ (1) NZ710860A (el)
PE (1) PE20151432A1 (el)
PH (1) PH12015501534B1 (el)
PL (1) PL2943185T3 (el)
PT (1) PT2943185T (el)
RS (1) RS61857B1 (el)
RU (1) RU2678324C2 (el)
SG (1) SG11201505349RA (el)
SI (1) SI2943185T1 (el)
UA (1) UA117233C2 (el)
WO (1) WO2014110245A1 (el)
ZA (1) ZA201505082B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190021180A (ko) * 2017-08-22 2019-03-05 아주대학교산학협력단 퇴행성 신경질환 치료용 복합 제형 조성물
JP7110366B2 (ja) * 2017-11-01 2022-08-01 エッジモント・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー・トラスト ロラゼパムのアルコール耐性経口用医薬組成物

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (el) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
CH647150A5 (de) * 1980-01-21 1985-01-15 Wellcome Found Zubereitung, enthaltend ein tranquillans und ein propiophenon.
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
IT1188212B (it) 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
US5273758A (en) 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
ES2179829T3 (es) 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd Preparacion de hidrogel de liberacion prolongada.
US5871776A (en) 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
EP1065936B1 (en) * 1998-03-23 2009-08-05 General Mills, Inc. Encapsulation of components into edible products
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
CA2366791A1 (en) * 1999-04-06 2000-10-12 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
US6500459B1 (en) * 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
CA2431205C (en) 2000-12-05 2005-08-23 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
EP1250937B1 (en) 2001-04-09 2009-05-13 Rohm And Haas Company Controlled dissolution of active ingredients
EP1414416A4 (en) 2001-07-10 2007-06-27 Teva Pharma DRUG DELIVERY SYSTEM FOR RISING OR DECLINING MEDICINAL PRODUCT LEAVES OR BIPHASIC ZERO ORDER
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
US20030050620A1 (en) * 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
CA2483827C (en) 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US20050031688A1 (en) * 2003-08-04 2005-02-10 Ayala William J. Positive wakeup pharmaceutical sleep system with compatible pre-bedtime administration
WO2005027877A1 (en) * 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US9205047B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
US8277840B2 (en) 2005-07-22 2012-10-02 Emcure Pharmaceuticals Limited Sustained release formulation of alprazolam
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CA2635594A1 (en) * 2005-12-30 2007-07-12 Advancis Pharmaceutical Corporation Gastric release pulse system for drug delivery
US20080031944A1 (en) * 2006-08-04 2008-02-07 Cima Labs Inc. Stabilization of lorazepam
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
PE20081229A1 (es) * 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US20100179170A1 (en) 2006-12-05 2010-07-15 Lisa Claire Du Toit Heterogeneously configured multiparticulate gastrointestinal drug delivery system
EP2285219B1 (en) * 2008-05-08 2018-07-18 Supernus Pharmaceuticals, Inc. Controlled release formulations of alprazolam
US20110217371A1 (en) 2008-11-10 2011-09-08 Amorepacific Corporation Controlled-release microparticles and method of preparing same
US20120135050A1 (en) 2010-07-08 2012-05-31 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
ES2856181T3 (es) 2021-09-27
US20160228378A1 (en) 2016-08-11
WO2014110245A1 (en) 2014-07-17
US20150110874A1 (en) 2015-04-23
MX2015008756A (es) 2016-03-31
JP2016504390A (ja) 2016-02-12
IL239777A0 (en) 2015-08-31
ZA201505082B (en) 2021-04-28
DK2943185T3 (da) 2021-02-15
SG11201505349RA (en) 2015-08-28
JP2017019880A (ja) 2017-01-26
PH12015501534A1 (en) 2015-10-05
JP6039823B2 (ja) 2016-12-07
KR20150118119A (ko) 2015-10-21
RU2015128915A (ru) 2017-02-10
CA2897302A1 (en) 2014-07-17
UA117233C2 (uk) 2018-07-10
LT2943185T (lt) 2021-03-10
IL239777B (en) 2019-03-31
PE20151432A1 (es) 2015-09-23
RS61857B1 (sr) 2021-06-30
SI2943185T1 (sl) 2021-04-30
PH12015501534B1 (en) 2015-10-05
US20150174078A1 (en) 2015-06-25
CN105209018A (zh) 2015-12-30
CA2897302C (en) 2022-05-31
HK1213770A1 (zh) 2016-07-15
PT2943185T (pt) 2021-02-18
HRP20210236T1 (hr) 2021-03-19
MX367364B (es) 2019-08-16
CN105209018B (zh) 2019-06-25
RU2678324C2 (ru) 2019-01-28
BR112015016304A2 (pt) 2017-07-11
HUE054005T2 (hu) 2021-08-30
US8999393B1 (en) 2015-04-07
NZ710860A (en) 2020-05-29
AU2014205440B2 (en) 2018-07-05
AU2014205440A1 (en) 2015-08-27
PL2943185T3 (pl) 2022-01-17
EP2943185A1 (en) 2015-11-18
CL2015001920A1 (es) 2016-01-29
EP2943185B1 (en) 2020-11-18
KR102318274B1 (ko) 2021-10-26
BR112015016304A8 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
CY1122113T1 (el) Φαρμακευτικες συνθεσεις για τη θεραπεια του ελικοβακτηριδιου του πυλωρου
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112018010671A2 (pt) dispositivos e métodos de distribuição de fármaco com mudança de forma
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
CU20160006A7 (es) Derivados de piperidinil-indol como inhibidores de factor de complemento b
NI201500140A (es) Compuestos y composiciones terapéuticos
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
PH12015502745A1 (en) 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
BR112015011430A2 (pt) composição para liberação imediata e prolongada
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
UY35091A (es) Formulaciones de liberacion modificada para oprozomib
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CL2015000610A1 (es) Derivados de isoxazolidina
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
BR112015016322A2 (pt) formulações de lorazepam de liberação controlada
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.